VERASTEM INC (VSTM)       0.6438  -0.02 (-3.04%)

Verastem (NASDAQ:VSTM) announces $60M private placement offering, trial results

Verastem Oncology (VSTM) on Tuesday announced a private placement offering of its preferred stock for up to $60M.The company said it had entered into an agreement to sell about 2.1M...

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Appoints Rob Gagnon to Board of Directors

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer

7 Cheap Biotech Stocks to Buy Now

These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.

Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Notable Thursday Option Activity: VSTM, TUP, CNK